quinuclidines has been researched along with amifostine anhydrous in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aframian, DJ; Nahlieli, O; Palmon, A | 1 |
| Johnstone, PA; Kahn, ST | 1 |
| Omar, SI; Tuszynski, J | 1 |
1 review(s) available for quinuclidines and amifostine anhydrous
| Article | Year |
|---|---|
Management of xerostomia related to radiotherapy for head and neck cancer.
Topics: Acupuncture Therapy; Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Palliative Care; Pilocarpine; Quinuclidines; Radiation-Protective Agents; Radiotherapy; Submandibular Gland; Thiophenes; Xerostomia | 2005 |
3 other study(ies) available for quinuclidines and amifostine anhydrous
| Article | Year |
|---|---|
[Future therapy strategies for salivary gland impairment].
Topics: Amifostine; Cranial Irradiation; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Quinuclidines; Radiation Injuries; Radiation-Protective Agents; Regeneration; Saliva; Salivary Glands; Thiophenes | 2004 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Salivary Glands; Thiophenes; Xerostomia | 2006 |
Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties.
Topics: Alkylation; Amifostine; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Drug Evaluation, Preclinical; Ellipticines; Heterocyclic Compounds, 4 or More Rings; Humans; Kinetics; Ligands; Mercaptoethylamines; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Mutation; Oxepins; Protein Binding; Pyrimidines; Quinuclidines; Tumor Suppressor Protein p53 | 2015 |